News
Luspatercept Improves Response Rates, Transfusion Independence for Lower-Risk MDS
“Overall, luspatercept led to durable and clinically meaningful responses beyond the achievement of the primary end point, supporting its use as the treatment of choice over ESAs in patients with transfusion-dependent lower-risk MDS–associated anemia who are ESA naive,” lead study author Amer Zeidan, MBBS, of Yale School of Medicine and Yale Cancer Center in New Haven, Connecticut, and coauthors, wrote in a poster of the data.
Source: Oncology Nursing News